{"id":"artefenomel-ferroquine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Artefenomel is a blood-stage antimalarial agent that inhibits the Plasmodium falciparum parasite's ability to infect red blood cells. Ferroquine is a liver-stage antimalarial agent that targets the parasite in the liver. The combination of artefenomel and ferroquine aims to provide a more effective treatment for malaria by targeting both the blood and liver stages of the parasite.","oneSentence":"Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:23.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated Plasmodium falciparum malaria"}]},"trialDetails":[{"nctId":"NCT02497612","phase":"PHASE2","title":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-07-25","conditions":"Plasmodium Falciparum Infection","enrollment":377},{"nctId":"NCT03660839","phase":"PHASE2","title":"Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-09-11","conditions":"Plasmodium Falciparum Infection","enrollment":140},{"nctId":"NCT04264130","phase":"PHASE2","title":"Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2018-07-31","conditions":"Schistosomiasis Haematobia","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Artefenomel-Ferroquine","genericName":"Artefenomel-Ferroquine","companyName":"Centre de Recherche Médicale de Lambaréné","companyId":"centre-de-recherche-m-dicale-de-lambar-n","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite. Used for Treatment of uncomplicated Plasmodium falciparum malaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}